Get the Stockscreener App
1.18
2.61%
0.03
After Hours:
1.20
0.02
+1.69%
Pliant Therapeutics Inc stock is traded at $1.18, with a volume of 1.24M.
It is up +2.61% in the last 24 hours and down -11.28% over the past month.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of integrin-based therapies. The company operates as a single reportable segment focused on developing and commercializing novel integrin-based treatments. Its lead product candidate, PLN-101095, is an oral small molecule targeting integrins for the treatment of solid tumors. The company also advances a pipeline of integrin-based programs across multiple disease areas through its proprietary drug discovery platform.
See More
Previous Close:
$1.15
Open:
$1.17
24h Volume:
1.24M
Relative Volume:
2.29
Market Cap:
$73.07M
Revenue:
$248.00K
Net Income/Loss:
$-149.34M
P/E Ratio:
-0.4846
EPS:
-2.4348
Net Cash Flow:
$-128.71M
1W Performance:
-1.67%
1M Performance:
-11.28%
6M Performance:
-24.84%
1Y Performance:
-14.49%
1-Day Range:
$1.14
$1.235
1-Week Range:
$1.13
$1.235
52-Week Range:
$1.09
$1.95
Pliant Therapeutics Inc Stock (PLRX) Company Profile
Name
Pliant Therapeutics Inc
Sector
Industry
Phone
650-481-6770
Address
331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
Compare PLRX vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PLRX
Pliant Therapeutics Inc
|
1.18 | 71.21M | 248.00K | -149.34M | -128.71M | -2.4348 |
VRTX
Vertex Pharmaceuticals Inc
|
436.58 | 110.90B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
629.68 | 73.20B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
776.26 | 49.71B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
286.27 | 38.32B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
144.37 | 30.97B | 742.00K | -1.37B | -1.07B | -7.0731 |
Pliant Therapeutics Inc Stock (PLRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-10-25 | Downgrade | JP Morgan | Neutral → Underweight |
| Mar-04-25 | Resumed | Cantor Fitzgerald | Neutral |
| Mar-04-25 | Downgrade | Needham | Buy → Hold |
| Mar-03-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Mar-03-25 | Downgrade | Stifel | Buy → Hold |
| Feb-10-25 | Downgrade | Canaccord Genuity | Buy → Hold |
| Feb-10-25 | Downgrade | Citigroup | Buy → Neutral |
| Feb-10-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Feb-10-25 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-10-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Feb-10-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Feb-10-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Sep-09-24 | Resumed | Leerink Partners | Outperform |
| Dec-08-23 | Initiated | Wells Fargo | Overweight |
| May-18-23 | Initiated | Canaccord Genuity | Buy |
| Apr-13-23 | Initiated | Robert W. Baird | Outperform |
| Dec-14-22 | Initiated | Stifel | Buy |
| Dec-07-22 | Initiated | JP Morgan | Overweight |
| Sep-01-22 | Initiated | Citigroup | Buy |
| Jul-20-22 | Initiated | SVB Leerink | Outperform |
| May-25-22 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-21 | Initiated | Oppenheimer | Outperform |
| Nov-24-21 | Initiated | RBC Capital Mkts | Outperform |
| Nov-03-21 | Initiated | H.C. Wainwright | Buy |
| Apr-20-21 | Initiated | BTIG Research | Buy |
| Apr-05-21 | Initiated | Citigroup | Buy |
| Jun-29-20 | Initiated | Citigroup | Buy |
| Jun-29-20 | Initiated | Cowen | Outperform |
| Jun-29-20 | Initiated | Needham | Buy |
| Jun-29-20 | Initiated | Piper Sandler | Overweight |
View All
Pliant Therapeutics Inc Stock (PLRX) Latest News
Atisama Therapeutics Advances RB042 into Multiple Ascending Dose cohorts of Phase 1 Trial and Appoints Bernard Coulie as Chair of the Board - ChartMill
TradingKey - TradingKey
Number of shareholders of Pliant Therapeutics, Inc. – MUN:9PT - TradingView
CCORF Downgrades Pliant Therapeutics(PLRX.US) to Hold Rating, Maintains Target Price $3 - Moomoo
A Quick Look at Today's Ratings for Pliant Therapeutics(PLRX.US), With a Forecast Between $2 to $3 - Moomoo
Pliant Therapeutics (PLRX) Advances Clinical Trials and Pipeline Development - GuruFocus
Pliant Therapeutics Q1 net loss narrows on lower expenses - TradingView
Pliant Therapeutics (NASDAQ: PLRX) cuts Q1 2026 net loss to $20M - Stock Titan
Pliant Therapeutics (PLRX) narrows Q1 2026 loss as PLN-101095 shows early responses - Stock Titan
Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results - ChartMill
Pliant Therapeutics (NASDAQ:PLRX) Stock Rating Lowered by Wall Street Zen - MarketBeat
PLRX (Pliant Therapeutics) quarterly loss narrower than feared; shares tick up as pipeline hopes support sentiment.Margin Improvement - newser.com
The industry tailwinds powering Pliant Therapeutics (PLRX) growth (Smart Money Flows) 2026-05-08Community Volume Signals - newser.com
Pliant CEO, CFO to join RBC healthcare fireside chat on May 19 - Stock Titan
PLRX SEC FilingsPliant Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Pliant Therapeutics Inc expected to post a loss of 36 cents a shareEarnings Preview - TradingView
Pliant Therapeutics (NASDAQ:PLRX) Upgraded at Wall Street Zen - MarketBeat
Pliant Therapeutics (PLRX) Initiates Key Clinical Trial for Canc - GuruFocus
Pliant Therapeutics Announces First Patient Dosed in FORTIFY, the Phase 1b Indication Expansion Trial Evaluating PLN-101095 in Patients with ICI-Refractory Solid Tumors - Investing News Network
Pliant Therapeutics begins trial of cancer drug combination By Investing.com - Investing.com South Africa
Pliant Therapeutics begins trial of cancer drug combination - Investing.com
Pliant Therapeutics Announces First Patient Dosed in - GlobeNewswire
Pliant Therapeutics (PLRX) price target decreased by 17.95% to 2.72 - MSN
Pliant Therapeutics Inc (FRA:9PT) Stock Price & 30 Year Financial Data - GuruFocus
Wall Street Zen Downgrades Pliant Therapeutics (NASDAQ:PLRX) to Sell - MarketBeat
Pliant Therapeutics (NASDAQ: PLRX) outlines 2026 virtual meeting, board changes and pay vote - Stock Titan
[ARS] PLIANT THERAPEUTICS, INC. SEC Filing - Stock Titan
Pliant Therapeutics, Inc. (PLRX) Presents at AACR Annual Meeting 2026Slideshow (NASDAQ:PLRX) 2026-04-21 - Seeking Alpha
Primary Sclerosing Cholangitis (PSC) Market is expected to Hit - openPR.com
Pliant Therapeutics (PLRX) Reports Promising Updates on PLN-101095 Trials - GuruFocus
Pliant Therapeutics (PLRX) Reports Promising Updates on PLN-1010 - GuruFocus
Pliant Therapeutics (PLRX) Stock: Movement Analysis (Breakout Watch) 2026-04-18Elite Trading Signals - Cổng thông tin điện tử tỉnh Lào Cai
Pliant presents updated cancer trial data at AACR meeting By Investing.com - Investing.com South Africa
Pliant Therapeutics presents updated Phase 1 data for PLN-101095 in ICI-refractory tumors - Traders Union
Pliant presents updated cancer trial data at AACR meeting - Investing.com
Pliant Therapeutics : Final AACR 2026 PLN10195 Yap - marketscreener.com
Pliant Therapeutics Says Pln-101095 Generally Well Tolerated; Most Common Trae Was Rash, One Grade 3 Trae Observed - TradingView
Pliant Therapeutics Announces Presentation of Updated Data - GlobeNewswire
Pliant Therapeutics, Inc. 8-K SEC Filing Details for April 14, 2026 – Company Information, Registered Securities, and NASDAQ Listing - Minichart
Pliant Therapeutics Announces Board Retirements and Option Repricing - TipRanks
COO Minnie Kuo’s PLRX options repriced to $1.33 exercise price (PLRX) - Stock Titan
Form 4Statement of changes in beneficial ownership of securities - ADVFN
PLIANT THERAPEUTICS (PLRX) reprices Lily Cheung stock options at $1.33 - Stock Titan
Form 8-KCurrent report - ADVFN
Pliant Therapeutics, Inc. (NASDAQ:PLRX) Given Consensus Recommendation of "Reduce" by Analysts - MarketBeat
Pliant Therapeutics (NASDAQ:PLRX) Shares Up 1.6%Should You Buy? - MarketBeat
If You Invested $1,000 in Pliant Therapeutics, Inc. (PLRX) - Stock Titan
Bull Run: Is Pliant Therapeutics Inc subject to activist investor interest2026 Catalysts & High Conviction Buy Zone Picks - baoquankhu1.vn
Inflation Data: Is Pliant Therapeutics Inc still a buy after recent gainsPortfolio Update Report & Technical Confirmation Trade Alerts - baoquankhu1.vn
Pliant Therapeutics Inc Stock (PLRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Pliant Therapeutics Inc Stock (PLRX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Cheung Lily | Chief Human Resource Officer |
Jan 20 '26 |
Sale |
1.28 |
7,534 |
9,644 |
44,847 |
| Coulie Bernard | President and CEO |
Jan 20 '26 |
Sale |
1.28 |
89,375 |
114,400 |
505,601 |
| Kuo Minnie | Chief Operating Officer |
Jan 20 '26 |
Sale |
1.28 |
6,917 |
8,854 |
37,806 |
2.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):